Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Sol-Gel Technologies Ltd. SLGL

Healthcare  —  Biotechnology
66.85 6.11 10.06% as of 25 Sep
Market cap
$198.9M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Sol-Gel Technologies Ltd. (SLGL) Business Profile

Updated before January 2025

Company Overview

Sol-Gel Technologies Ltd. (SLGL) is a clinical-stage specialty pharmaceutical company that focuses on the development and commercialization of topical dermatological treatments. Founded in 1997 and headquartered in Ness Ziona, Israel, the company leverages its proprietary sol-gel technology to create innovative and effective solutions for skin conditions. The company was founded by Dr. Alon Seri-Levy, who also serves as its Chief Executive Officer. Under his leadership, SLGL has grown into a prominent player in the dermatology space, with a strong emphasis on research and development (R&D) and strategic partnerships.

The company operates with a mission to improve the lives of patients suffering from skin diseases by providing advanced, patient-friendly topical treatments. Its leadership team includes experienced professionals with expertise in pharmaceuticals, dermatology, and biotechnology, ensuring a robust strategy for growth and innovation.

Core Business Segments

Dermatological Treatments

SLGL specializes in developing topical treatments for common skin conditions such as acne, rosacea, and other dermatological disorders. The company’s proprietary sol-gel technology enables the formulation of drugs with improved efficacy, stability, and patient compliance.

Key Products:

  • Epsolay®: A topical cream for the treatment of inflammatory lesions of rosacea. Approved by the FDA, Epsolay® utilizes encapsulated benzoyl peroxide to reduce irritation and improve patient outcomes.
  • Twyneo®: A combination of tretinoin and benzoyl peroxide for the treatment of acne vulgaris. Twyneo® is designed to deliver both active ingredients simultaneously while minimizing irritation.

Generic Dermatological Products

In addition to its proprietary products, SLGL develops generic dermatological drugs in collaboration with leading pharmaceutical companies. These generics are based on the sol-gel technology platform, offering high-quality alternatives to existing treatments.

Research and Development Services

SLGL also provides R&D services to its partners, leveraging its expertise in sol-gel technology to co-develop innovative dermatological solutions. This segment contributes to the company’s revenue stream and strengthens its position as a technology leader in the dermatology space.

Business Model

SLGL operates on a hybrid business model that combines proprietary product development, strategic partnerships, and licensing agreements. The company generates revenue through:

  1. Product Sales: Revenue from the commercialization of proprietary products like Epsolay® and Twyneo®.
  2. Partnership Agreements: Collaborations with pharmaceutical companies for the development and commercialization of generic and branded dermatological products.
  3. Licensing and Royalties: Income from licensing its sol-gel technology to partners and receiving royalties on product sales.

This diversified approach allows SLGL to mitigate risks and maintain a steady revenue stream while focusing on innovation and market expansion.

Strategic Direction

SLGL is committed to expanding its product portfolio and market presence through the following strategies:

  1. Pipeline Expansion: The company is actively developing new products for unmet needs in dermatology, including treatments for psoriasis and other chronic skin conditions.
  2. Geographic Expansion: SLGL aims to enter new markets, particularly in Europe and Asia, to broaden its global footprint.
  3. Sustainability Goals: The company is exploring eco-friendly manufacturing processes and sustainable packaging solutions to align with global environmental standards.
  4. Technological Innovation: Continued investment in R&D to enhance its sol-gel technology platform and develop next-generation dermatological treatments.

Competitive Landscape

SLGL operates in a competitive market, facing challenges from both large pharmaceutical companies and smaller specialty firms. Key competitors include:

  • Galderma: A global leader in dermatology with a broad portfolio of prescription, over-the-counter, and aesthetic products.
  • Bausch Health Companies Inc.: Known for its dermatology and eye health products.
  • Allergan (a subsidiary of AbbVie): Offers a range of dermatological treatments, including Botox and other aesthetic solutions.
  • Amgen: Focuses on biologics for dermatological conditions like psoriasis.

SLGL differentiates itself through its proprietary sol-gel technology, which provides a competitive edge in terms of product efficacy and patient compliance.

Risk Factors

Despite its strengths, SLGL faces several risks that could impact its business:

  1. Market Dependence: Heavy reliance on the success of Epsolay® and Twyneo® for revenue generation.
  2. Regulatory Challenges: Stringent FDA and EMA approval processes for new products.
  3. Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers for raw materials and production.
  4. Competitive Pressure: Intense competition from established players and new entrants in the dermatology market.
  5. Financial Risks: As a clinical-stage company, SLGL may face challenges in securing funding for R&D and commercialization efforts.

Recent Developments

  • FDA Approvals: The recent FDA approvals of Epsolay® and Twyneo® mark significant milestones for SLGL, enabling the company to commercialize these products in the U.S. market.
  • Partnerships: SLGL has entered into strategic collaborations with leading pharmaceutical companies to co-develop and commercialize generic dermatological products.
  • Technological Advancements: The company continues to enhance its sol-gel technology platform, focusing on improving drug delivery and patient outcomes.
  • Global Developments: The COVID-19 pandemic has impacted supply chains and delayed clinical trials, but SLGL has implemented measures to mitigate these challenges and ensure business continuity.

Investment Considerations

Strengths:

  • Proprietary sol-gel technology with proven efficacy.
  • FDA-approved products with strong market potential.
  • Diversified revenue streams through partnerships and licensing.
  • Experienced leadership team and robust R&D capabilities.

Risks:

  • Dependence on a limited number of products for revenue.
  • Regulatory and competitive challenges.
  • Financial risks associated with being a clinical-stage company.

Conclusion

Sol-Gel Technologies Ltd. is a pioneering company in the dermatology space, leveraging its innovative sol-gel technology to develop effective and patient-friendly treatments. With FDA-approved products like Epsolay® and Twyneo®, a strong pipeline, and strategic partnerships, SLGL is well-positioned for growth. However, the company must navigate regulatory, competitive, and financial challenges to achieve its long-term goals. Overall, SLGL represents a promising investment opportunity for those seeking exposure to the specialty pharmaceutical sector, particularly in dermatology.